Log In Sign up
The largest database of trusted experimental protocols

Cd3 apc cy7 clone sk7

Manufactured by BioLegend
Visit Supplier
Sourced in United States

CD3-APC/Cy7 (clone SK7) is a fluorochrome-conjugated monoclonal antibody that binds to the CD3 antigen, which is expressed on the surface of T cells. This product is intended for use in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Cell therapy systems dynabeads cd3 cd28, by Thermo Fisher Scientific (2 mentions) Hrgm csf, by STEMCELL (2 mentions) Fal h5241, by ACROBiosystems (2 mentions) Pma ionomycin, by Merck Group (2 mentions) 7 aad, by BD (2 mentions) Annexin 5 pe, by BD (2 mentions) Cd56 pe vio770, by Miltenyi Biotec (1 mentions) Cd16 apcvio770, by Miltenyi Biotec (1 mentions) Propidium iodide, by Miltenyi Biotec (1 mentions) Staphylococcal enterotoxin b, by Toxin Technology (1 mentions) Ki67 pe clone b56, by BD (1 mentions) Facsaria flow cytometer, by BD (1 mentions) Cd4 apc h7 clone rpa t4, by BD (1 mentions) Cd4 bv605 clone rpa t4, by BD (1 mentions) P24 fitc clone kc57, by Beckman Coulter (1 mentions) Facscanto flow cytometer, by BD (1 mentions) Cytofix cytoperm kit, by BD (1 mentions)

Close spelling variants of this product

CD3 APC-Cy7 (SK7; CD3-APC (clone SK7, CD3 (clone SK7, CD3-APC-Cy7 CD3 (SK7, APC-Cy7 CD3-APC

5 protocols using cd3 apc cy7 clone sk7

1

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
α-CD2-PerCP-Vio770 (clone LT2, Miltenyi Biotec), NFL1 viability dye (OncoImmunin), CD56-BV421 (clone HCD56, Biolegend), CD2-BV510 (clone RPA-2.10, Biolegend), CD4-PEVio770 (clone REA623, Miltenyi Biotec), CD45RA-APC (clone REA562, Miltenyi Biotec), CD3-APC/Cy7 (clone SK7, Biolegend), propidium iodide (Miltenyi Biotec), CCR7-BV421 (clone 3D12, BD Biosciences), CD27-PE (clone REA499, Miltenyi Biotec), CD16-APCVio770 (clone REA426, Miltenyi Biotec) and CD56-PEVio770 (clone REA196, Miltenyi Biotec).
Tomalka A.G., Resto-Garay I., Campbell K.S, & Popkin D.L. (2018). In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Frontiers in Immunology, 9, 2552.
+ Open protocol
+ Expand
2

T-cell Proliferation and Chemokine Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
MSCs were seeded onto 96-well plates with appropriate densities. PBMCs from random donor were added into each well with the final concentration of 0.1 × 106 cells per well. 500 ng/mL staphylococcal enterotoxin B (SEB) (Toxin Technology, Sarasota, FL) was used to stimulate the T cells in the PBMCs. Ki67 proliferation assay was performed to measure T-cell proliferation after 4 days. For Ki67 proliferation assay, intracellular flow cytometry staining was performed with BD Cytofix and Cytoperm procedure with the antibodies CD3APCCy7 (Clone SK7) (Biolegend, USA) and Ki67 PE (Clone B56) (BD Biosciences, USA) according to manufacturer instructions (BD Biosciences, San Jose, CA). Samples were acquired in BD FACS Aria flow cytometer, and the results were analyzed in FlowJo software. For non-contact cocultures, MSCs are cultured on the bottom of the well and SEB-activated PBMCs were cultured on the transwell membrane (0.4 µM). Three days later MSCs were lysed and RNA was isolated. Total RNA is converted into cDNA (Qiagen, USA). Quantitative real-time PCR was performed to identify the expression of chemokines.
Lipat A.J., Cottle C., Pirlot B.M., Mitchell J., Pando B., Helmly B., Kosko J., Rajan D., Hematti P, & Chinnadurai R. (2022). Chemokine Assay Matrix Defines the Potency of Human Bone Marrow Mesenchymal Stromal Cells. Stem Cells Translational Medicine, 11(9), 971-986.
+ Open protocol
+ Expand
3

Multicolor Flow Cytometry of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh heparinized blood via Ficoll–Hypaque density gradient centrifugation (Pharmacia, Uppsala, Sweden). Multicolor flow cytometry with fluorescent conjugated antibodies obtained from BioLegend (San Diego, USA) were as follows: CD3-APC-Cy7 (clone SK7), CD8-Percp/Cyanine5.5 (clone SK1), CD56-BV421 (clone HCD56), CCR5-FITC (clone J418F1), and CXCR4-APC (clone RG5). CD4-APC-H7 (clone RPA-T4) and CD4-BV605 (clone RPA-T4) were obtained from BD Biosciences (New Jersey, USA). PBMCs were first stained at 4°C for 30 min with fluorescent antibodies under dark conditions. Cells were then permeabilized using a Cytofix/Cytoperm Kit (BD Bioscience) and stained with p24-PE (clone KC57) or p24-FITC (clone KC57) from Beckman Coulter (Eurocenter S.A, California, USA). The cells were fixed in 0.5% formaldehyde and analyzed using a FACSCantoTM flow cytometer (BD Biosciences). The data were analyzed using the FlowJo software (TreeStar).
Gao L., Jiao Y.M., Ma P., Sun L., Zhao H., Guo A.L., Fan X., Zhang C., Song J.W., Zhang J.Y., Lu F, & Wang F.S. (2022). Characterization and distribution of HIV-infected cells in semen. Emerging Microbes & Infections, 11(1), 860-872.
+ Open protocol
+ Expand
4

Modulating CART19 Cell Survival

Check if the same lab product or an alternative is used in the 5 most similar protocols
GM-CSFWT CART19 or GM-CSFKO CART19 cells were stimulated with PMA/Ionomycin (Millipore Sigma, Ontario, Canada), CD19+ cell line Nalm6, or Cell Therapy Systems Dynabeads CD3/CD28 (Life Technologies, Oslo, Norway) at different time points (0hr, 1hr, 2hr, 4hr, 6hr, 1 day, 2 days, 3 days, 4 days, or 5 days). The following amounts were used for stimulation: 50 ng/mL of PMA, 1 ug/mL of ionomycin, 3:1 ratio of beads:cells, and 1:1 ratio of Nalm6:CART19. Then, cells were spun and washed with flow buffer, followed by incubation in the dark with the following reagents: CD3 (clone SK7) APC-Cy7 (344818, BioLegend, San Diego, CA, USA), Annexin V PE (556421, BD Biosciences, San Jose, CA, USA), 7-AAD (559925, BD Biosciences, San Jose, CA), and 1X annexin binding buffer (1:10 dilution of 10X ABB) (556454, BD Biosciences, San Jose, CA, USA). Then, the expression of Annexin V and 7-AAD on CD3 cells was measured via flow cytometry. For assays including recombinant exogenous hrGM-CSF (78190, Stemcell Technologies, Vancouver, Canada), the following doses were added: 100 and 1000 ng/mL. For exogenous FasL protein (FAL-H5241, ACRO Biosystems, Newark, DE, USA), the following dose was used: 50ng/mL.
Cox M.J., Roman C.M., Tapper E.E., Siegler E.L., Chappell D., Durrant C., Ahmed O., Sinha S., Mwangi R., Scott N.S., Hefazi M., Schick K.J., Horvei P., Ruff M.W., Can I., Adada M., Bezerra E., Fonkoua L.A., Parikh S.A., Kay N.E., Sakemura R, & Kenderian S.S. (2022). GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia, 36(6), 1635-1645.
+ Open protocol
+ Expand
5

Modulating CART19 Cell Survival

Check if the same lab product or an alternative is used in the 5 most similar protocols
GM-CSFWT CART19 or GM-CSFKO CART19 cells were stimulated with PMA/Ionomycin (Millipore Sigma, Ontario, Canada), CD19+ cell line Nalm6, or Cell Therapy Systems Dynabeads CD3/CD28 (Life Technologies, Oslo, Norway) at different time points (0hr, 1hr, 2hr, 4hr, 6hr, 1 day, 2 days, 3 days, 4 days, or 5 days). The following amounts were used for stimulation: 50 ng/mL of PMA, 1 ug/mL of ionomycin, 3:1 ratio of beads:cells, and 1:1 ratio of Nalm6:CART19. Then, cells were spun and washed with flow buffer, followed by incubation in the dark with the following reagents: CD3 (clone SK7) APC-Cy7 (344818, BioLegend, San Diego, CA, USA), Annexin V PE (556421, BD Biosciences, San Jose, CA, USA), 7-AAD (559925, BD Biosciences, San Jose, CA), and 1X annexin binding buffer (1:10 dilution of 10X ABB) (556454, BD Biosciences, San Jose, CA, USA). Then, the expression of Annexin V and 7-AAD on CD3 cells was measured via flow cytometry. For assays including recombinant exogenous hrGM-CSF (78190, Stemcell Technologies, Vancouver, Canada), the following doses were added: 100 and 1000 ng/mL. For exogenous FasL protein (FAL-H5241, ACRO Biosystems, Newark, DE, USA), the following dose was used: 50ng/mL.
Cox M.J., Roman C.M., Tapper E.E., Siegler E.L., Chappell D., Durrant C., Ahmed O., Sinha S., Mwangi R., Scott N.S., Hefazi M., Schick K.J., Horvei P., Ruff M.W., Can I., Adada M., Bezerra E., Fonkoua L.A., Parikh S.A., Kay N.E., Sakemura R, & Kenderian S.S. (2022). GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia, 36(6), 1635-1645.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!